Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
- NTNU - Norwegian University of Science and Technology
- NTNU Norwegian University of Science and Technology
- University of Bergen
- Norwegian University of Life Sciences (NMBU)
- UiT The Arctic University of Norway
- NHH Norwegian School of Economics
- Simula UiB AS
- University of Agder (UiA)
- University of Oslo
-
Field
-
IT programmes of study at all levels. Our subject areas include hardware, algorithms, visual computing, AI, databases, software engineering, information systems, learning technology, HCI, CSCW, IT
-
, algorithms, visual computing, AI, databases, software engineering, information systems, learning technology, HCI, CSCW, IT operations and applied data processing. The Department has groups in both Trondheim
-
or similar international approval/allowance certificate for the work with genetically modified organisms is a requirement a track record of publications in the field of neurodegenerative diseases
-
, quantitative genetics and structural variation Personal qualities Personal qualities and suitability for the position will be emphasized. The successful candidate is expected to contribute to an active research
-
of genetic causes of POI. 4. Immunotherapy for autoimmune oophoritis. The project is interdisciplinary and seeks to develop new diagnostic tools and therapeutic strategies for POI, including a clinical study
-
detection and classification algorithms using measured and/or simulated data, such as current pulses from cable faults (breakdown), partial discharges and external noise. In addition to being part of
-
the development of headache, and how headache impacts the Norwegian economy. The project applies advanced methods in epidemiology, causal inference, genetic epidemiology, and machine learning. As a PhD candidate in
-
epidemiology, causal inference, genetic epidemiology, and machine learning. As a PhD candidate in the project, you will: Actively participate in group meetings, design statistical analysis plans in collaboration
-
: WP1 will analyze large-scale registry data from the Nordic countries and England to assess the safety of modern ASMs. WP2 will investigate genetic, epigenetic, and pharmacological markers of ASM-related